Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rituximab and hematological malignancy].

Kiyohiko Hatake1, Yuko Mishima, Yasuhito Terui

  • 1Division of Medical Oncology, The Cancer Chemotherapy Center of the Japanese Foundation for Cancer Research.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

International journal of clinical oncology·2026
Same author

Factors associated with aggregate formation in cold-stored platelets.

Vox sanguinis·2026
Same author

Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma.

Cancers·2026
Same author

Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity.

Leukemia·2026
Same author

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Cureus·2026
Same author

Bilateral orbital masses caused by IgG4-expressing MALT lymphoma in the right side and IgG4-related ophthalmic disease in the left side: A case report.

Modern rheumatology case reports·2026
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Rituximab, a chimeric anti-CD20 monoclonal antibody, offers a new strategy for treating CD20+ B cell lymphomas. It shows efficacy alone or with chemotherapy, with manageable side effects like infusion reactions.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Context:

  • CD20 is a B cell antigen crucial for targeting B cell malignancies.
  • Monoclonal antibodies are engineered for targeted therapy, exemplified by chimeric antibodies derived from murine and human cDNA.
  • Rituximab is an established anti-CD20 monoclonal antibody with demonstrated efficacy in B cell lymphomas.

Purpose:

  • To explore the therapeutic potential of Rituximab as a single agent and in combination therapies for CD20-positive B cell lymphomas.
  • To investigate the mechanisms of action, including apoptosis induction, complement-dependent cytotoxicity, and antibody-dependent cell-mediated cytotoxicity.
  • To evaluate the synergistic effects of Rituximab with chemotherapy regimens (CHOP, ICE, DHAP) and stem cell transplantation for various B cell malignancies.

Summary:

Related Experiment Videos

  • Rituximab, a chimeric anti-CD20 monoclonal antibody, has been developed for targeted therapy against CD20+ B cell lymphomas.
  • It demonstrates efficacy as a single agent and in combination with chemotherapy (e.g., CHOP regimen), presenting a novel treatment strategy.
  • Potential mechanisms include apoptosis induction and cell-mediated cytotoxicity, with synergy observed with chemotherapy and stem cell transplantation in treating lymphomas, CLL, and Waldenstrom's macroglobulinemia.

Impact:

  • Rituximab offers a promising therapeutic option for patients with CD20+ B cell lymphomas, including chronic lymphocytic leukemia (CLL) and Waldenstrom's macroglobulinemia.
  • Combination therapies involving Rituximab and chemotherapy agents or stem cell transplantation enhance treatment outcomes.
  • While generally well-tolerated, careful monitoring for infusion reactions is necessary post-administration.